



ImmcoStripe™ Liver LIA

Line immunoassay (LIA) for the detection of AMA-M2, SLA, SP100, GP210, LC1, Nup62, LKM, Ro52, and CENPB IgG antibodies

IVD

For in vitro Diagnostic use

PRODUCT INSERT

REF

6040

Liver LIA

20 Determinations

INTENDED USE

Line immunoassay for the qualitative detection of AMA-M2, SLA, SP100, GP210, LC1, Nup62, LKM, Ro52, and CENPB IgG antibodies in human serum.

SUMMARY AND EXPLANATION

Autoimmune hepatitis (AIH) is a distinct chronic inflammatory liver disease, characterized by the attack of the immune system directed against “self” antigens, especially those expressed in the liver.^{1, 2} It occurs in both sexes and all age groups; however, women are more likely victims of AIH than men. Hepatomegaly and splenomegaly are the most common pathological findings associated with AIH. Abnormalities of the immune system that mark AIH include autoantibodies to liver antigens, hyper-gammaglobulinemia, and an increased CD4/CD8 ratio in peripheral blood and liver. Liver-Kidney Microsomal (LKM1) antibodies can be induced not only by autoimmune mechanisms, but also by drugs such as tienic acid, dihydralazine, halothane, phenytoin, phenobarbital, carbamazepine and by Hepatitis C and D infections.⁴⁻⁶ The International Autoimmune Hepatitis Group categorizes AIH into two separate disease groups: Type 1 and Type 2. This distinction is based on the presence of marker autoantibodies in serum of affected patients.⁵ AIH Type 1 is characterized by antinuclear autoantibodies (ANA’s) and smooth-muscle antibodies (SMA’s). Type 1 is the more common type of AIH, accounting for 60-70% of patients with AIH. Type 2 is a somewhat rarer disease (prevalence of AIH Type 2 is about 10 cases per million) characterized by the presence of autoantibodies against microsomal antigens of liver and kidney (LKM) and/or LC1, and the absence of ANA and SMA3. The autoantigen associated with LKM1 antibodies is cytochrome P4502D6. Antibodies to LKM1 occur predominantly in patients with AIH but can also be detected in some patients with HCV infection.⁷⁻¹⁰

Primary Biliary Cirrhosis (PBC) is a disease of the liver characterized by inflammatory obliteration of the intrahepatic bile ducts.¹²⁻¹⁵ PBC is characterized by the presence of anti-mitochondrial antibodies (AMA). Studies have identified that the predominant autoantigen in PBC is an inner mitochondrial membrane associated enzyme complex. ImmcoStripe™ LIA detects autoantibodies to all three E2 subunits of the functionally similar mitochondrial dehydrogenase

complexes (PDC-E2, BCOADC-E2 and OGDC-E2).¹⁵⁻¹⁹ In addition, the LIA includes Sp100, Ro52, CenpB (also seen in some cases of SLE), gp210 (highly specific to PBC), nucleoporin p62 (Nup62).

The ImmcoStripe™ Liver LIA panel is capable of simplifying the detection of autoantibodies against 9 key antigens which may also be observed by IFA screening on Immuglo™ HEP-2 and/or HEP-2 and Liver Tissue Slides. The following antigens are immobilized on the test strips: AMA-M2, SLA, SP100, GP210, LKM, LC-1, NUP-62, SSA/Ro-52 and CenpB. In addition to the antigen lines, a cut-off, serum and conjugate control line is provided in the bottom of the strip.

PRINCIPLES OF PROCEDURE

To perform the test, strips are incubated with diluted patient serum. In positive sera antibodies specifically bind to one or more of the test lines on the strip. The strips are washed according to the protocol, and then the pre-diluted, ready-to-use conjugate is added to the test strips. After incubation and wash steps, the ready-to-use substrate is added to the strips. During a 10 minute incubation, conjugate and substrate binding produces visible blue/purple lines for serum, conjugate and cut-off control lines. If the sample is positive for any of the antigen coated test lines, it will show a reaction more intense than the cut-off line. Reactions are read visually and reported as positive, negative or equivocal (comparable to cut-off line).

Materials Provided

Liver LIA [REF] 6040

Kits contain sufficient reagents to perform 20 determinations.

20 x	[STRIP LIVER LIA]	Line Immunoassay Test Strips , containing antinuclear antigen coated test lines and control lines. Ready for use.
1 x 120 µl	[CONTROL + LIA]	Positive Control (red cap). Contains human serum positive for one or more antigens.
1 x 30 ml	[CONJ LIA]	IgG Conjugate .
1 x 30 ml	[SUBSTRATE]	Enzyme Substrate (amber bottle). Ready for use. Protect from light .
1 x 50 ml	[DIL]	Diluent
1 x 50 ml	[BUF WASH LIA]	Wash Buffer Concentrate . * Reconstitute to one liter with deionized or distilled water or as needed proportionally.
2 x		LIA 10 well Assay Trays
1 x		Report/Scoring Sheet

* Contains Proclin300 preservative.

Materials Required But Not Provided

- Clean 1000 ml graduated cylinder

EN

- Non-serrated forceps (Filter forceps)
- Rocker or rotating platform shaker
- Absorbent paper or paper towels
- Deionized or distilled water
- Squeeze bottles to hold diluted wash buffer or distilled water
- Pipettes capable of delivering 10 to 1000 µl
- Disposable pipette tips
- Timer

REAGENTS

Storage and Preparation

Store all reagents at 2-8°C; **do not freeze.**

All reagents must be brought to room temperature (18-25°C) and mixed thoroughly prior to use. Do not use if reagent is not clear or if insoluble precipitate is present. The reagents are stable until the indicated expiration date when stored at 2-8°C and protected from contamination, or as stated below after opening and/or reconstitution.

- Antigen coated test strips **STRIP|LIVER|LIA** are ready for use. Please allow the test strip bag to reach the room temperature before opening to avoid condensation and associated deterioration. Please re-pack unused test strips and store at 2-8°C in dark and dry conditions.
- Sample Diluent **DIL** is ready to use. After opening, Sample Diluent is stable for at least 8 weeks when stored properly and protected from microbial or chemical contamination.
- Reconstitute 1 part **BUF|WASH|LIA** into 19 parts of distilled or deionized water to produce 1 liter of Wash Buffer. Wash Buffer is stable for at least 8 weeks after reconstitution when stored properly and protected from microbial contamination.
- **CONJ|LIA** and **SUBSTRATE** are stable for at least 8 weeks after opening when stored properly and protected from microbial contamination. **SUBSTRATE** is light sensitive and must be stored in the provided amber colored bottle.

Antigen strips can only be used once. Do not interchange components of different lots. Do not use reagents beyond expiration date indicated on labels.

Precautions

All human derived components used have been tested for HBsAg, HCV, HIV-1 and 2 and HTLV-I and found negative by FDA required tests. However, human blood derivatives and patient specimens should be considered potentially infectious. Follow good laboratory practices in storing, dispensing and disposing of the above materials.¹¹

EN

WARNING – Proclin 300 is a preservative. Upon disposal of liquids containing Proclin 300, flush with large volumes of water to dilute the components below active levels.

Instructions should be followed exactly as they appear in this kit insert to ensure valid results. Do not interchange kit components with those from other sources. Follow good laboratory practices to minimize microbial and cross contamination of reagents when handling. Do not use kit components beyond expiration date on the labels.

SPECIMEN COLLECTION AND HANDLING

Only serum specimens should be used in this procedure. Specimens with gross hemolysis, elevated lipids or microbial contamination may interfere with the performance of the test and therefore must not be used. Store specimens at 2°-8°C for no longer than one week. For longer storage, serum specimens should be frozen. It is recommended that frozen specimens be tested within one year. Avoid repeated freezing and thawing of samples.

PROCEDURE

Procedural Notes

- Read Product Insert carefully before starting with the assay.
- Let serum specimens and test reagents equilibrate to room temperature for approximately 30 minutes prior to starting the test procedure. Return all unused specimens and reagents to the refrigerator promptly after use.
- Proper washing technique is critical to the satisfactory performance of the assay.
- Handle test strips with clean forceps or gloves only. Avoid touching the white antigen coated areas.
- The test lines are placed above the cut-off, serum and conjugate control lines as described in the schematic (Figure 1). Serum and conjugate control lines appear on the same piece of nitrocellulose at the bottom of the strip.
- Assign specimen identification numbers to the respective strips on the Report Form. Each strip has the strip number and lot number printed on the bottom for traceability.
- Complete all other relevant information on the Report Form prior to starting the assay.

Test Method

Step 1 Using gloves or blunt forceps, peel off the required number of strips. Care should be taken not to touch the antigen coated areas with bare hands or pointed forceps.

EN

- Step 2** Place required number of **STRIP|LIVER|LIA** labeled side up into individual wells of the assay tray.
- Step 3** Pipet 1.5 ml of **DIL** into each well; make sure that the strips are completely submerged under the liquid.
- Step 4** Incubate the strips in **DIL** for at least 10 minutes on a rocker. The blue color in coated antigen and control locations starts to disappear as the membrane is soaked.
- Step 5** Pipet 15 µl of serum or positive control sample into the appropriate wells to obtain a 1:101 dilution. Incubate 60 minutes (±5 min.) at room temperature on a rocker or rotating shaker.
- Step 6** WASH: Aspirate sample solution into waste container. Thoroughly wash strips with the **reconstituted** Wash Buffer by squirting approximately 2ml of solution directly onto strips. Wash strips with gentle agitation for 5 minutes and aspirate solution into waste container. Repeat the wash two more times.
- Caution: Complete washing of the strips between incubations is crucial to obtain valid results. Improper washing will result in high background staining. Do not allow the strips to become dry at any step during the assay.
- Step 7** Pipet 1.0 ml of **CONJ|LIA** into each well. Incubate 30 minutes (±5 min) at room temperature on rocker or rotating shaker.
- Step 8** Repeat Step 6.
- Step 9** Pipet 1.0 ml **SUBSTRATE|TMB** into each well and incubate with gentle shaking 10 minutes at room temperature in reduced light. The serum and conjugate control lines develop intense color after incubation in substrate. The cut-off control line develops into a blank to faintly colored line after the incubation.
- Step 10** To stop the reaction, rinse strips 2x with distilled/deionized water by squirting approximately 2ml of water directly onto strips followed by aspiration. Do not soak/wash for more than 10 minutes as this may result in decreased sensitivity of the developed colored lines.
- Step 11** Using blunt forceps remove strips from assay tray and place them gently onto absorbent paper and allow them to dry. Let the strips dry before analysis or affixing them on the report/scoring sheet.

Quality Control

Procedural Controls: Each strip has three procedural controls for the addition of serum and conjugate and a cut-off line for determining the weak or negative reactions.

Positive and Negative controls are available as optional components and may be run for additional quality control.

Individual labs are expected to optimize the substrate development time by +/- 4 minutes based on the blot processor or manual methodology. It is

recommended that the cut-off line should be faintly visible to the eye, post incubation with substrate.

Interpretation

The test strips contain control lines at the bottom and test line above the controls. The bottom end of the test strip (near serial number) has three control lines: the cut-off line, the serum control line and the conjugate control line from top to bottom. The cut-off allows the technician to determine the test result as positive, negative or indeterminate (+/-). The two procedure control lines ensure the addition of specimen, conjugate and substrate.

Compare the reaction of the test lines with those of the controls. Use of a magnifying glass can assist in observation of weak reactions.

- As labeled in Figure 1, the serum and conjugate control lines should be clearly positive indicating a successful experiment. The cut-off is a faint line with variation in intensity based on the experimental conditions. The schematic in Figure 1 shows an example test line. In the Liver LIA (Figure 2) there are 9 test lines and 3 control lines. The test line development depends on the sample. Positive reactions can occur in varying intensities from weak to strong. **Weak reactions should be compared with intensity of the provided cut-off line within the strip.** Reactions that are distinctly darker or denser than the intensity of the cut-off line should be considered positive.
- Strips may show a homogeneous or discolored background due to various interfering factors in lipemic or hemolytic sera. This effect can also be seen if the test strips are not sufficiently blocked or accidentally allowed to dry up during the assay.
- In case of weak positive and negative reactions, the reacted line intensity should be compared to cut-off line to determine the result as negative (weaker intensity than the cut-off line) or equivocal (+/-; indistinguishable from cut-off line). Visualization of weak reactions is improved when the strips are completely dry. Equivocal samples should be confirmed by an alternate method.




Figure 1: Schematic of reacted LIA strips with one test line.

Figure 2: Schematic of Report Sheet

- Dried strips can be assembled in the provided report/scoring sheet. The plastic protective flap is permanently affixed to the report sheet on the left edge. Carefully peel the plastic flap in the right to left direction like a page of the book. Place the reacted strips on the adhesive tape in the respective slot and cover the plastic flap back in place. The protective plastic flap is designed to be reusable for multiple sessions of experiments and the strips can be assembled in respective slots. The technician can use the form to record the lot numbers of used reagents, specimen number and results/comments.

LIMITATIONS OF PROCEDURE

Only serum specimens should be used in this procedure. Grossly hemolyzed, lipemic or microbially contaminated specimens may interfere with the performance of the test and should not be used. Do not store specimen at 2-8°C more than a week. For longer storage, serum specimens should be frozen. Avoid repeated freezing and thawing of samples.

The Liver LIA should only be used as an aid to diagnosis. Positive results may be found in other autoimmune conditions or certain infectious diseases. Hence, results should be evaluated and interpreted by a medical authority in light of the patient's clinical history and other laboratory findings.

EXPECTED VALUES

At 1:40 titer, elevated levels of anti-nuclear and cytoplasmic antibodies may be present in up to 30% individuals in a "normal" population as determined by IFA methodology. At a titer of 1:320 positivity rate in normal population has been reported to drop to approximately 3%. Incidence of autoantibody positivity varies to a great extent based on the specific tissue antigens, studies and selected cohort of specimens. Certain autoantigens are specific to a disease while antibodies to many autoantigens are seen in multiple systemic and organ specific autoimmune disorders. The expected values in a normal population are negative on LIA. LIA panels are designed to provide optimal sensitivity and specificity. It is recommended to confirm the positive result by an alternate methodology.

PERFORMANCE CHARACTERISTICS

Antigen Specificities

The Liver LIA is able to detect autoantibodies to the following LIA antigens: AMA-M2, SLA, SP100, GP210, LKM, LC-1, NUP-62, SSA/Ro-52 and CenpB. Refer to Figure 2 for individual antigen and control line positions.

Cross-reactivity

A panel of potentially cross-reactive autoimmune disease sera from conditions not associated with Autoimmune Liver Diseases was tested using the Liver LIA test. 3 out of 153 determinations demonstrated a positive reaction indicating a specificity of 98% in this population.

Interference

Interference was studied by mixing sera with known levels of autoantibodies for each analyte with potentially interfering serum samples and studying deviation from expected results. No significant interference was demonstrated for the following substances at the levels indicated: Hemoglobin (5 mg/ml), Bilirubin (0.4 mg/ml), Rheumatoid Factor (200 EU equivalent) and Triglycerides (25 mg/ml). Interference studies have been performed according to CLSI guidelines (publication EP7-A2).

Reproducibility

Assays of samples in the negative range, equivocal and positive range were performed to determine qualitative reproducibility from run to run and operator to operator. Results produced 100% qualitative agreement.


**REFERENCES • ΠΑΡΑΠΟΜΠΕΣ • BIBLIOGRAFÍA • REFERENZEN •
RÉFÉRENCES • REFERENCES • REFERÊNCIAS**

1. Meyer zum Buschenfelde KH, Dienes, HP. Autoimmune hepatitis, definition – classification – histopathology – immunopathogenesis. *Virchows Arch* 429:1-12, 1996.
2. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. *Hepatology* 28:360-365, 1998
3. Chazouilleres O, Wendum D, Serfaty L et al. Primary biliary cirrhosis – autoimmune hepatitis overlap syndrome: clinical features and response to therapy. *Hepatology* 28:297-301, 1998.
4. van den Berg AP. Autoimmune hepatitis: pathogenesis, diagnosis and treatment. *Scand J Gastroenterol* 225:66-9, 1998.
5. Czaja AJ. Diagnosis and therapy of autoimmune liver disease. *Med Clin North Am* 80:973994, 1996.
6. Yamamoto AM, Cresteil D, Homberg JC and Alvarez F. Characterization of anti-liverkidney microsome antibody (Anti-LKM1) from hepatitis C virus – positive and – negative sera. *Gastroenterol* 104:1762-1767, 1993.
7. Choudhuri K, Gregorio GV, Mieli-Vergani G, and Vergani D. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. *Hepatology* 28:1177-1181, 1998.
8. Ma Y, Peakman M, Lobo-Yeo A et al. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. *Clin Exp Immunol* 97:94-99, 1994.
9. Manns MP, Griffin KJ, Sullivan KF and Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. *J. Clin Invest* 88:1370-1378, 1991.
10. Gueguen M, Boniface O, Bernard O et al. Identification of the main epitope on human cytochrome P450IID6 recognized by anti-liver kidney microsome antibody. *J Autoimm* 4:607-615, 1991.
11. Biosafety in Microbiological and Biomedical Laboratories. Centers for Disease Control, National Institutes of Health, 1993 [HHS Pub. No. (CDC) 93-8395].
12. Kaplan MM. Primary biliary cirrhosis, Review. *N Engl J Med*; 1987, 316:521-528.
13. Colucci G, Schaffner F and Paronetto F. In situ characterization of the cell-surface antigens of the mononuclear cell infiltrates and bile duct epithelium in primary biliary cirrhosis. *Clin Immunol & Immunopathol*; 1986, 41 :35.
14. Patrick SC, Leung, Ross L et al. Antimitochondrial antibodies in primary biliary cirrhosis. *Seminars Liv Dis*;1997, 17:61 -69.
15. Berg PA, Klein R, Lindenborn-Fotinos J et al. Heterogeneity of anti-mitochondrial antibodies. *Lancet*; 1982, 2:1423-1426.
16. Yea men SJ, Fussey SP, Danner OJ, and Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. *Lancet*; 1988, 2:1067-1070.
17. Van de Water J, Gershwin ME, Leung Pet al. The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase. *J Exp Med*; 1988, 167:1791 -1799.
18. Fussey SM, Ali ST, Guest JR et al. Reactivity of primary biliary cirrhosis sera with *Escherichia coli* dihydrolipoamide acetyltransferase (E2p); characterization of the main immunogenic region. *Proc Natl Acad Sci USA*; 1990, 87:3987-3991
19. N. Zurgil, R. Bakimer, M. Kaplan et al. Anti-pyruvate dehydrogenase autoantibodies in primary biliary cirrhosis. *J Clin Immunol*; 1991, 5:239-245.50

For technical assistance please contact:



 **IMMCO Diagnostics, Inc.**
60 Pineview Drive
Buffalo, NY 14228-2120
Telephone: (716) 691-0091
Fax: (716) 691-0466
Toll Free USA/Canada: 1-800-537-TEST
E-Mail: info@immcodiagnostics.com



EMERGO Europe
Molenstraat 15, 2513 BH, The Hague,
The Netherlands
www.emergogroup.com

or your local product distributor

MAY 2015

Document No. PI6040